When Embryos Don't Reach Blastocyst Stage: Is Early Embryo Transfer a Valid Option?

Q: Is early embryo transfer better than blastocyst transfer?

**The answer changes depending on which measure you use.** Per fresh transfer, blastocyst transfer wins (live birth OR 1.27). Measured as the cumulative live birth rate from all embryos of one egg retrieval, the two strategies came out comparable (PMID: 42431250). And waiting for blastocysts makes having nothing to transfer 2 to 4 times more likely — which weighs most heavily on those who retrieve few eggs. Note that "potential for development within the uterine environment" is a hypothesis, not a trial finding. Discuss your treatment history, embryo status and egg count with your specialist.

Facing a situation where your embryos don't develop to the blastocyst (Day 5/6) stage during IVF can be profoundly disheartening. It's perfectly normal to feel disappointed or frustrated when things don't go as hoped. However, in such circumstances, an early embryo transfer (Day 2/3) might be a viable option. This article, from a fertility specialist's perspective, will delve into the scientific rationale behind early embryo transfer when blastocyst development fails, and what you should consider as a patient.

The Importance and Challenges of Blastocyst Development

In IVF, culturing fertilised eggs to the "blastocyst" stage (Day 5 or Day 6) genuinely does perform better per transfer. A Cochrane review of 32 randomised controlled trials covering 5,821 couples (Glujovsky D, et al. Cochrane Database Syst Rev. 2022. PMID: 35588094) found a higher live birth rate per fresh transfer with blastocyst-stage transfer (odds ratio 1.27, 95% CI 1.06 to 1.51; 15 studies, 2,219 women; low-quality evidence) and a higher clinical pregnancy rate (OR 1.25, 95% CI 1.12 to 1.39; 32 studies, 5,821 women; moderate-quality evidence). The review translates this as: if 31% of women have a live birth after fresh cleavage-stage transfer, between 32% and 41% would do so after fresh blastocyst-stage transfer.

However, not all fertilised eggs develop into blastocysts. The main reasons for blastocyst failure include egg or sperm quality, or abnormalities during the early stages of embryonic development after fertilisation. While significant efforts are made to optimise culture conditions, there are inherent limitations.

The cost that is easy to overlook: having nothing to transfer

The same Cochrane review also quantifies what waiting for a blastocyst costs.

Failure to transfer any embryo was more common in the blastocyst group — OR 2.50 (95% CI 1.76 to 3.55; 17 studies, 2,577 women; moderate-quality evidence). In the review's own words: if 1% of women have no embryos transferred in a planned fresh cleavage-stage transfer, between 2% and 4% probably have none transferred in a planned fresh blastocyst-stage transfer.
Fewer women had surplus embryos to freeze in the blastocyst group — OR 0.48 (95% CI 0.40 to 0.57; 14 studies, 2,292 women; low-quality evidence). If 60% have embryos frozen after cleavage-stage transfer, between 37% and 46% would after blastocyst-stage transfer.

"How well one transfer performs" and "how many women from one egg retrieval end up with a baby" are two different questions.

Measured cumulatively per retrieval, the difference disappears

The Cochrane review itself says it is uncertain whether blastocyst-stage transfer improves the cumulative clinical pregnancy rate. A later systematic review and meta-analysis focused on cumulative live birth rate (Busnelli A, et al. Fertil Steril. 2026. PMID: 42431250) concluded the two strategies give comparable results overall.

4 RCTs, 2,432 women — risk ratio 1.10 (95% CI 1.00 to 1.22; very low certainty). A post hoc sensitivity analysis using the Knapp-Hartung method made the effect non-significant (RR 1.10, 95% CI 0.95 to 1.28).
7 observational studies, 151,530 ART cycles — OR 1.03 (95% CI 0.95 to 1.12; very low certainty).

An important caveat: the RCTs enrolled good-prognosis patients, so the women this article is written for — those whose embryos do not reach the blastocyst stage — were not studied. In the subgroup where fewer than two transfers were performed per patient, the blastocyst strategy did better (RR 1.14, 95% CI 1.06 to 1.23; 3 studies, 620 women), but the certainty there is also very low.

What is Early Embryo Transfer, and Why is it Considered?

Early embryo transfer involves transferring an embryo at the Day 2 or Day 3 stage (cleavage stage) into the uterus. Typically, embryos undergo early development in the fallopian tubes, reaching the uterine lining around Day 5 for implantation. The idea behind early embryo transfer is that returning the embryo to this more "natural" environment inside the body sooner may offer benefits that cannot be replicated in an in-vitro culture setting.

Key reasons why early embryo transfer might be considered when blastocyst development fails include:

Securing a transfer opportunity: This is the reason the numbers above actually support. Waiting for blastocysts raises the chance of having nothing to transfer to 2–4% (versus about 1% at the cleavage stage), so a Day 2/3 transfer secures the opportunity itself.
Limitations of in-vitro culture (a hypothesis, not a finding): The idea is that some embryos which arrest in the incubator might have continued in the uterus. No trial has shown that an embryo destined to arrest in culture develops when transferred earlier. It is a reasonable hypothesis; it is not established.
Reduced time lag (also a hypothesis): The argument that less time outside the body means less stress has not been confirmed as an improvement in pregnancy rates.

Pros and Cons of Early Embryo Transfer

Pros

Secured transfer opportunity: An embryo can be transferred even when blastocyst development is uncertain (supported: OR 2.50 above).
Better chance of having embryos to freeze: More women end up with surplus embryos frozen when freezing at the cleavage stage (supported: OR 0.48 above).
Reduced emotional burden: The anxious wait to see whether embryos reach the blastocyst stage is shorter (this one has not been measured).

Cons

Lower performance per transfer: As above, live birth and clinical pregnancy rates per fresh transfer are higher with blastocyst transfer. The usual explanation is that embryos unable to keep developing have not yet been filtered out at the cleavage stage.
Harder embryo selection: It is more difficult to identify which early embryos have the best potential.
On multiple pregnancy (correcting what this article used to say): This article previously stated that early embryo transfer might carry a slightly higher risk of multiple pregnancy. That is not what the Cochrane review found. Multiple pregnancy was OR 1.05 (95% CI 0.83 to 1.33; low-quality evidence) — uncertain either way — and a sensitivity analysis limited to low-risk-of-bias studies with equal numbers of embryos transferred suggested blastocyst transfer probably increases multiple pregnancy. Miscarriage was also uncertain (OR 1.12, 95% CI 0.90 to 1.38; low-quality). What drives multiple pregnancy risk is how many embryos are transferred, not the stage.

For more detailed information on IVF, you can also explore this article.

When Should You Consider Early Embryo Transfer?

Early embryo transfer is not a universally recommended option. It is most commonly considered in situations such as:

History of very low blastocyst formation rates in previous IVF cycles.
When a limited number of eggs were retrieved, and there's a high risk of having no transferable embryos if cultured to the blastocyst stage.
Repeated blastocyst transfers have failed to result in implantation or blastocyst development.

The ultimate decision should be made after a comprehensive discussion with your fertility specialist, considering factors such as your age, treatment history, embryo quality, and the number of available embryos. Please don't hesitate to discuss all your options and expectations with your doctor. To learn more about fertility treatment options, please visit our website.

Frequently Asked Questions (FAQ)

Q1: Is early embryo transfer better than blastocyst transfer?

A1: The answer changes depending on which measure you use. Per fresh transfer, blastocyst transfer wins (live birth OR 1.27). Measured as the cumulative live birth rate from all embryos of one egg retrieval, the two strategies came out comparable (PMID: 42431250). And waiting for blastocysts makes having nothing to transfer 2 to 4 times more likely — which weighs most heavily on those who retrieve few eggs. Note that "potential for development within the uterine environment" is a hypothesis, not a trial finding. Discuss your treatment history, embryo status and egg count with your specialist.

Q2: Does blastocyst failure mean my eggs or sperm quality is poor?

A2: While egg and sperm quality can certainly influence blastocyst development, it's not the only factor. Other elements, such as random abnormalities during early embryonic development after fertilization or compatibility with the in-vitro culture environment, can also play a role. Often, the exact cause cannot be fully identified, and you should not blame yourself.

Q3: If I repeatedly undergo early embryo transfer without success, are there other options?

A3: Factors beyond embryo quality, such as the state of the endometrium, can be discussed with your doctor. However, this article previously named endometrial scratching and immune-modulating therapy here. Neither has the backing to be offered that way, and we are correcting it.

Endometrial scratching (deliberately creating a small injury in the lining): The Cochrane review updated in May 2026 (Perera AK, et al. Cochrane Database Syst Rev. 2026. PMID: 42138348; 22 RCTs, 7,194 women, primary analysis restricted to 8 low-risk-of-bias studies, 4,402 participants) finds the effect on live birth unclear: OR 1.12 (95% CI 0.98 to 1.28; moderate-certainty evidence), a result consistent with an increase, no effect, or a small reduction. Clinical pregnancy was similar (OR 1.08, 95% CI 0.95 to 1.23). Meanwhile it probably does cause mild to moderate pain and some bleeding. The previous (2021) version concluded that current evidence does not support routine use, and this update did not change that conclusion.
Immune-modulating therapy: We could not identify established evidence supporting immunosuppressive treatment for recurrent implantation failure. It should not have been listed here as an option.

On transfer strategy in recurrent implantation failure, there is a retrospective cohort study (Gao J, et al. Front Endocrinol. 2023. PMID: 37745696). In 1,774 cycles at a single centre, "sequential ET" — a Day 3 embryo followed by a blastocyst within one cycle — gave a higher clinical pregnancy rate than double cleavage-stage transfer (50.7% vs 40.4%), was similar to double blastocyst transfer (47.1%), and had less multiple pregnancy (17.0% vs 25.5% and 27.6%). Because the groups were not randomised, they were not comparable, and this cannot be read causally. In the same study the blastocyst group had a higher early miscarriage rate than the cleavage-stage group (17.2% vs 8.1%) but a lower ectopic pregnancy rate (0.4% vs 3.0%) — results pointing in opposite directions.

Summary

When embryos do not develop to the blastocyst stage, early embryo transfer is a valid option — but not for the reason usually given. It is not that the uterus grows embryos better. What the evidence supports is this: waiting for blastocysts makes having nothing to transfer 2 to 4 times more likely, leaves fewer women with embryos to freeze, and does not clearly improve the cumulative result per egg retrieval. Blastocyst transfer does perform better per transfer — but that performance is unusable if there is no embryo to transfer.

One thing should be stated plainly: there are almost no comparative trials in women whose embryos fail to reach the blastocyst stage, or with a poor prognosis. The Cochrane review closes by saying that future trials should evaluate women with a poor prognosis. Most of the numbers in this article come from good-prognosis populations.

Prioritising your emotional well-being while talking things through with a trusted fertility specialist remains the most important part of building a plan that fits your situation.

About the evidence in this article

Of the two Cochrane reviews at the centre of this article, the endometrial injury review states it received no specific funding. The authors of the embryo-stage review are affiliated with private reproductive medicine centres and clinics (CEGYR among them); please check the originals for affiliations and conflict of interest disclosures. No culture-media manufacturer or device company involvement is disclosed.
Level of evidence: in the embryo-stage Cochrane review, live birth is low quality and clinical pregnancy moderate quality. The review names its main limitations as serious imprecision and serious risk of bias, associated with failure to describe acceptable methods of randomisation. The cumulative live birth meta-analysis is very low certainty. The recurrent implantation failure study is observational (a retrospective cohort), single-centre and not randomised. None of this supports firm claims.

References

Glujovsky D, et al. "Cleavage-stage versus blastocyst-stage embryo transfer in assisted reproductive technology." Cochrane Database Syst Rev. 2022. PMID: 35588094
Busnelli A, et al. "Effect of blastocyst-stage versus cleavage-stage strategy on cumulative live birth rate in assisted reproductive technology: a systematic review and meta-analysis." Fertil Steril. 2026. PMID: 42431250
Perera AK, et al. "Endometrial injury in women undergoing in vitro fertilisation (IVF)." Cochrane Database Syst Rev. 2026. PMID: 42138348
Gao J, et al. "Sequential embryo transfer versus double cleavage-stage embryo or double blastocyst transfer in patients with recurrent implantation failure with frozen-thawed embryo transfer cycles: a cohort study." Front Endocrinol (Lausanne). 2023. PMID: 37745696
Japan Society for Reproductive Medicine. Guidelines for Reproductive Medicine 2021.

Written by the same author — a general guide to preconception care and fertility planning: https://www.amazon.com/dp/B0F771VNV5?tag=ttcguide-enblog-22